CAS: 927961-18-0; 4-(1-(Benzo[d]Thiazol-6-Ylsulfonyl)-5-Chloro-1H-Indol-2-yl)Butanoic Acid
物理性质
- 沸点690.9±65.0 °C at 760 mmHg
- 闪点371.6±34.3 °C
- 密度1.6±0.1 g/cm3
- pKa:4.69±0.10(预测)
- LogP:4.3
- 折射率1.727
- 蒸汽压0.0±2.3 mmHg at 25°C
- 溶解性DMF:50.0(Max Conc. mg/mL);114.97(Max Conc. Mm) DMSO:79.0(Max Conc. mg/mL);181.65(Max Conc. Mm) DMSO:Pbs (Ph 7.2) (1:4):0.2(Max Conc. mg/mL);0.46(Max Conc. Mm) Ethanol:0.2(Max Conc. mg/mL);0.46(Max Conc. Mm)
- 外观形态白色至浅棕色结晶性固体
- 储存条件储存在 -20°C
- 产品应用该化合物是一种过氧化性扩散者活化受体(PPAR)的抗体.
上下游产品
Methyl 4-[1-(1,3-Benzothiazol-6-Ylsulfonyl)-5-Chloroindol-2-Yl]Butanoate 927961-17-9合成工艺路线路线简述
- 927961-17-9 = 927961-18-0
反应条件:1.1 Reagents: Lithium Hydroxide,Monohydrate Solvents: Tetrahydrofuran,Water; 3 H,Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Acidified
标题:Design,Synthesis,And Evaluation Of A Novel Series Of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (Ppar) α/γ/δ Triple Activators: Discovery Of Lanifibranor,A New Antifibrotic Clinical Candidate
作者:Boubia,Benaissa; Poupardin,Olivia; Barth,Martine; Binet,Jean; Peralba,Philippe; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2018 卷标:61(6) 页码:2246-2265]
= 927961-18-0 [标题:Reaction Conditions
标题:Pharmaceutical Composition And Its Use
参考文献:China]
927961-17-9 = 927961-18-0
反应条件:1.1 Reagents: Lithium Hydroxide Solvents: Tetrahydrofuran,Water; 3 H,Rt1.2 Reagents: Hydrochloric Acid Solvents: Water; Acidified,Rt
标题:New 1-Aryl- And 1-Heteroarylsulfonyl-1H-Indole-2-Alkanoic Acid Derivatives,Their Preparation And Use As Ppar Activators
参考文献:France]
= 927961-18-0 [标题:Reaction Conditions
标题:Design,Synthesis,And Biological Evaluation Of Triazolone Derivatives As Potent Pparα/δ Dual Agonists For The Treatment Of Nonalcoholic Steatohepatitis
作者:Feng,Zhiqi; Xiang,Jiehao; Liu,Hui; Li,Jiaxin; Xu,Xiangrui; Et Al
参考文献:Journal Of Medicinal Chemistry 日期:2022 卷标:65(3) 页码:2571-2592]
= 927961-18-0 [标题:Reaction Conditions
标题:Pharmaceutical Composition And Use Thereof
参考文献:World Intellectual Property Organization
📜Methyl 4-[1-(1,3-Benzothiazol-6-Ylsulfonyl)-5-Chloroindol-2-Yl]Butanoate 以83的收率获得产物拉尼兰诺
参考文献:Method Of Treating Conditions Involving Ppar-Receptors With Indole Compounds
标题:Method Of Treating Conditions Involving Ppar-Receptors With Indole Compounds
摘要:本发明涉及一种符合以下式(I)的吲哚化合物,所述吲哚化合物的定义详见权利要求书,以及此类化合物的药学上可接受的加盐物,含有此类化合物的制药组合物,制备此类化合物的方法,以及它们作为药理活性物质的用途,特别是在治疗高甘油三酯血症,高脂血症,高胆固醇血症,糖尿病,内皮功能障碍,心血管疾病,炎症性疾病和神经退行性疾病方面的用途.
海关参考信息
- 2903919090-氯苯
2905121000-正丙醇
2905130000-正丁醇
2912110000-甲醛 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:WO-2025045973-A1
优先权日:2023-08-31
标题 :Synthesis of lanifibranor intermediate
发明人：BOUBIA BENAÃ?SSA; GONZALEZ JÉRÔME; BELL FRÉDÉRIC
权利人:INVENTIVA
摘要:The present disclosure is directed to a process for preparing a compound of formula (I), which comprises a palladium-free coupling reaction between N-(4-chloro-2-iodo-phenyl)-1,3-benzothiazole-6-sulfonamide and methyl 5-hexynoate in the presence of a copper catalyst.
专利号:US-12358903-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; FARAND JULIE; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
专利号:US-11739065-B2
优先权日:2016-06-13
标题 :FXR (NR1H4) modulating compounds
发明人：BLOMGREN PETER A; CURRIE KEVIN S; GEGE CHRISTIAN; KROPF JEFFREY E; XU JIANJUN
权利人:GILEAD SCIENCES INC
摘要:The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Bruni C, Praino E, Allanore Y, Distler O, Gabrielli A, Iannone F, Matucci-Cerinic M. Use of biologics and other novel therapies for the treatment of systemic sclerosis. Expert Rev Clin Immunol. 2016 Dec
12:1-14. [Epub ahead of print]
合成参考文献
参考文献:10.1007/978-3-031-15820-9_18
摘要:Goldenberg M, Noll P, Sampath S, Trotter SC. 12-Year-Old-Girl with a White Indented Plaque of the Frontal Scalp and Forehead. 2022. In: Clinical Cases in Dermatology.
参考文献:10.1007/978-3-662-62484-5_21
参考文献:10.1007/978-3-031-26681-2_6
摘要:Ansquer JC. The PPAR System in Diabetes. 2023. In: Contemporary Diabetes.
参考文献:10.1038/s41401-022-00860-3
摘要:Yang Y, Xie L, Zhang N, Zhou D, Liu T, Wu J. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis. Acta Pharmacologica Sinica. 2022 Feb 21;43(5):1180–90. doi: 10.1038/s41401-022-00860-3.
参考文献:10.1007/978-3-031-33548-8_14
摘要:Mihai C, Mihai B, Prelipcean CC. Type 2 Diabetes Mellitus and Insulin Resistance in Nonalcoholic Fatty Liver Disease. 2023. In: Essentials of Non-Alcoholic Fatty Liver Disease.
📝 需求与反馈
尽可能描述清楚需求与问题信息
